JP2014528446A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528446A5
JP2014528446A5 JP2014534619A JP2014534619A JP2014528446A5 JP 2014528446 A5 JP2014528446 A5 JP 2014528446A5 JP 2014534619 A JP2014534619 A JP 2014534619A JP 2014534619 A JP2014534619 A JP 2014534619A JP 2014528446 A5 JP2014528446 A5 JP 2014528446A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
azetidin
imidazole
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014534619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/058220 external-priority patent/WO2013052395A1/en
Publication of JP2014528446A publication Critical patent/JP2014528446A/ja
Publication of JP2014528446A5 publication Critical patent/JP2014528446A5/ja
Withdrawn legal-status Critical Current

Links

JP2014534619A 2011-10-06 2012-10-01 1,3−置換アゼチジンpde10阻害剤 Withdrawn JP2014528446A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544065P 2011-10-06 2011-10-06
US61/544,065 2011-10-06
PCT/US2012/058220 WO2013052395A1 (en) 2011-10-06 2012-10-01 1,3-substituted azetidine pde10 inhibitors

Publications (2)

Publication Number Publication Date
JP2014528446A JP2014528446A (ja) 2014-10-27
JP2014528446A5 true JP2014528446A5 (enExample) 2015-11-19

Family

ID=48044097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534619A Withdrawn JP2014528446A (ja) 2011-10-06 2012-10-01 1,3−置換アゼチジンpde10阻害剤

Country Status (8)

Country Link
US (1) US9365562B2 (enExample)
EP (1) EP2763672B1 (enExample)
JP (1) JP2014528446A (enExample)
AR (1) AR088258A1 (enExample)
AU (1) AU2012318874A1 (enExample)
CA (1) CA2851082A1 (enExample)
TW (1) TW201321369A (enExample)
WO (1) WO2013052395A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500682A1 (en) 2011-09-27 2014-05-12 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
TW201422610A (zh) * 2012-11-15 2014-06-16 Merck Sharp & Dohme 作爲pde10抑制劑之經二級醇取代之三唑
WO2014078216A1 (en) * 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
US9359348B2 (en) 2012-11-15 2016-06-07 Merck Sharp & Dohme Corp. Cyclopropyl imidazopyridine PDE10 inhibitors
EP2922823B1 (en) 2012-11-20 2018-10-31 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
US9273033B2 (en) 2012-11-20 2016-03-01 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as PDE10 inhibitors
ES2480341B1 (es) * 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
FR3040057A1 (fr) * 2015-08-13 2017-02-17 Inventiva Composes de type azetidine carboxylique
US10583269B2 (en) 2016-06-01 2020-03-10 Becton, Dickinson And Company Magnetized catheters, devices, uses and methods of using magnetized catheters
US20200199136A1 (en) * 2017-08-28 2020-06-25 Acurastem Inc. Pikfyve kinase inhibitors
ES2976515T3 (es) 2018-10-05 2024-08-02 Annapurna Bio Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
US20230135152A1 (en) * 2020-02-11 2023-05-04 AcuraStem Incorporated Pikfyve kinase inhibitors
WO2025049402A1 (en) * 2023-08-28 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037079A1 (en) * 1997-02-19 1998-08-27 Berlex Laboratories, Inc. N-heterocyclic derivatives as nos inhibitors
AU2003222786A1 (en) * 2002-04-18 2003-10-27 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
EP1863797A1 (en) * 2005-03-23 2007-12-12 AstraZeneca AB 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
EP1877385A1 (en) * 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
JP2009539884A (ja) * 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムaデルタ−9デサチュラーゼのインヒビターとしてのアゼチジン誘導体
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
PT2698062E (pt) * 2006-12-28 2015-10-19 Abbvie Inc Inibidores da poli (adp-ribose) polimerase
WO2009074300A2 (en) 2007-12-13 2009-06-18 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
MX2012013128A (es) * 2010-05-13 2013-03-20 Amgen Inc Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10.
US8785467B2 (en) 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
CA2845578C (en) 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors

Similar Documents

Publication Publication Date Title
JP2014528446A5 (enExample)
JP2016512259A5 (enExample)
CA2592986C (en) Heteroaromatic quinoline compounds
JP2014521711A5 (enExample)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
JP2014531465A5 (enExample)
ME02416B (me) Trpv4 antagonisтi
AU2012318874A1 (en) 1,3-substituted azetidine PDE10 inhibitors
JP2014518214A5 (enExample)
JP2017533946A5 (enExample)
JP2018522046A5 (enExample)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
SI2763982T1 (en) Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases
EP1979343A2 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
US20170173026A1 (en) Aminoquinazoline and pyridopyrimidine derivatives
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JPWO2020231808A5 (enExample)
JP2017500364A5 (enExample)
CA2899904A1 (en) Flap modulators
JP2016514717A5 (enExample)
US10894784B2 (en) Heteroarylbenzimidazole compounds
JP2016522231A5 (enExample)
JP2020529419A5 (enExample)
JP2020523309A5 (enExample)